Eledon Pharmaceuticals, Inc. (ELDN)

Eledon Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	6.8	22.81	20.55	4.61	56.41	84.83
Short-Term Investments	81.95	110.53	119.63	46.49	-	-
Cash & Short-Term Investments	88.76	133.34	140.18	51.1	56.41	84.83
Cash Growth	-17.49%	-4.88%	174.31%	-9.41%	-33.51%	-25.71%
Other Receivables	0.43	0.51	0.63	-	-	-
Receivables	0.43	0.51	0.63	-	-	-
Prepaid Expenses	3.53	1.83	2.82	4.94	3.08	3.48
Other Current Assets	0.38	0.01	0.1	0.09	0.03	0.03
Total Current Assets	93.09	135.69	143.73	56.13	59.52	88.35
Property, Plant & Equipment	0.45	0.61	0.93	0.37	0.74	0.77
Goodwill	-	-	-	-	-	48.65
Other Intangible Assets	32.39	32.39	32.39	32.39	32.39	32.39
Other Long-Term Assets	0.17	0.32	0.36	0.19	0.15	0.4
Total Assets	126.09	169.01	177.41	89.07	92.79	170.55

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	3.21	3.63	5.83	0.97	2.2	1.81
Accrued Expenses	8.19	14.36	5.43	2.55	3.91	2.22
Current Portion of Leases	0.38	0.36	0.31	0.38	0.36	0.37
Total Current Liabilities	11.79	18.34	11.58	3.9	6.48	4.4
Long-Term Leases	0.09	0.28	0.64	-	0.38	0.4
Long-Term Deferred Tax Liabilities	2.19	2.19	2.18	1.75	1.75	1.75
Other Long-Term Liabilities	40	11.42	44.87	76.21	-	-
Total Liabilities	54.06	32.23	59.27	81.86	8.61	6.55

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	39.1	55.77	55.75	0.02	0.01	0.01
Additional Paid-In Capital	504.9	482.19	417.95	270.89	287.03	278.88
Retained Earnings	-471.86	-401.2	-355.59	-319.4	-202.87	-114.9
Comprehensive Income & Other	-0.11	0.02	0.03	-	-	-
Total Common Equity	72.03	136.78	118.14	-48.49	84.18	164
Shareholders' Equity	72.03	136.78	118.14	7.21	84.18	164
Total Liabilities & Equity	126.09	169.01	177.41	89.07	92.79	170.55

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	0.47	0.64	0.95	0.38	0.75	0.77
Net Cash (Debt)	88.29	132.7	139.22	50.72	55.66	84.06
Net Cash Growth	-17.31%	-4.69%	174.50%	-8.88%	-33.78%	-26.29%
Net Cash Per Share	0.88	1.62	2.86	2.05	3.90	5.67
Filing Date Shares Outstanding	81.26	75.85	59.88	24.81	13.78	14.31
Total Common Shares Outstanding	80.97	75.54	59.9	24.21	13.78	14.31
Working Capital	81.3	117.34	132.15	52.23	53.04	83.95
Book Value Per Share	0.89	1.81	1.97	-2.00	6.11	11.46
Tangible Book Value	39.65	104.39	85.75	-80.87	51.8	82.96
Tangible Book Value Per Share	0.49	1.38	1.43	-3.34	3.76	5.80

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: May 13, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 19, 2026

Data Sources Report a data error